Factors affecting the delay of antidepressant effect in responders to Nortriptyline and Phenelzine
Anastasios Georgotas, Robert E. McCue, Thomas B. Cooper, Narmada Nagachandran, Arnold J. Friedhoff
Abstract
Anastasios Georgotas, Robert E. McCue, Thomas B. Cooper, Narmada Nagachandran, Arnold J. Friedhoff
Abstract
Seventy-six elderly depressed patients who had responded to either nortriptyline or phenelzine after a trial of up to 3 months were examined. The mean week of response was nearly 6 weeks. Patients who were more severely depressed took longer to respond. Patients with endogenous depression responded sooner on nortriptyline than did patients with nonendogenous depression. For patients on nortriptyline, lower plasma levels in the early weeks of treatment may delay response while differences in platelet monoamine oxidase inhibition in the early weeks of treatment do not appear to affect week of response for patients on phenelzine.
OpenAlex reports 50 citations for this work. Citation counts describe recorded attention and do not establish research quality.
A contribution statement is not available in the OpenAlex record.
Method details are not available in the OpenAlex metadata.
Findings are not separately available in the OpenAlex metadata.
Limitations are not available in the OpenAlex metadata.
Application details are not available in the OpenAlex metadata.
Seventy-six elderly depressed patients who had responded to either nortriptyline or phenelzine after a trial of up to 3 months were examined. The mean week of response was nearly 6 weeks. Patients who were more severely depressed took longer to respond. Patients with endogenous depression responded sooner on nortriptyline than did patients with nonendogenous depression. For patients on nortriptyline, lower plasma levels in the early weeks of treatment may delay response while differences in platelet monoamine oxidase inhibition in the early weeks of treatment do not appear to affect week of response for patients on phenelzine.
Key concepts: Phenelzine, Nortriptyline, Antidepressant, Monoamine oxidase inhibitor, Depression (economics), Medicine, Internal medicine, Endogenous depression